NasdaqHealth CarePharmaceutical PreparationsCARSON CITY, NV

BioVie Inc. BIVI

Ask your AI

Estimated market cap $12.12M10.72M shares, shares as of Nov 5, 2026CIK 1580149

Insider trades, 12 mo

4 buys · 0 sells

$49.1K bought, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

15.9% of shares · 5 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in BioVie Inc.'s latest quarterly report, compared with the one before.

Filed Nov 6, 2026 · Quarter ended Sep 30, 2026

AI No AI summary for this 10-Q: the draft did not pass our accuracy checks.

Compared with the 10-K for the period ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in BioVie Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

4 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Aug 28, 2026. Insiders have two business days to file.

Recent insider trades

Joseph M. Palumbo Chief Medical Officer	Aug 28 Form 4 ↗	Buy	+$10.5K 4,843 sh @ $2.16	-45.7%
Amy Suzon Chappell Director	Aug 28 Form 4 ↗	Buy	+$1,570 727 sh @ $2.16	-45.7%
Joanne Wendy Kim Chief Financial Officer	Aug 28 Form 4 ↗	Buy	+$5,450 2,500 sh @ $2.18	-45.7%
Cuong V. Do President & CEO, Director	Aug 27 Form 4 ↗	Buy	+$31.6K 15,210 sh @ $2.08	-46.2%
Cuong V. Do President & CEO, Director	Aug 7, 2025 Form 4 ↗	Buy	— 5,000 sh	-80.5%

All BIVI insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

1.71M shares

27 funds report BIVI. Values checked against market prices.

Funds own 20% of shares (Q2 2026)

38 funds hold the stock.

Q3 2026: 16% · 5,560 of ~8,900 funds reported so far

Q2 2025<0.1%
Q3 202516%
Q4 202515%
Q1 202614%
Q2 202620%
Q3 2026 (so far)16%

Q3 2026. 6 new, 5 added to, 1 trimmed, 16 exited since Q2 2026.

Top 13F holders
#
1	Morgan Stanley 13F ↗	1.05M	$1.6M	+73.2%
2	Jane Street Group, LLC 13F ↗	230,662	$350.6K	+543.2%
3	Acadian Asset Management LLC 13F ↗	80,826	$122.0K	New
4	Geode Capital Management, LLC 13F ↗	75,774	$115.2K	+7.1%
5	State Street Corp 13F ↗	73,103	$111.1K	New
6	Vanguard Capital Management LLC 13F ↗	70,906	$107.8K	unchanged
7	Philadelphia Trust Co 13F ↗	50,010	$76.0K	unchanged
8	Vanguard Fiduciary Trust Co 13F ↗	37,557	$57.1K	unchanged
9	StoneX Group Inc. 13F ↗	15,983	$26.4K	New
10	UBS Group AG 13F ↗	8,091	$12.3K	+272.0%

2 of these funds report values in thousands of dollars; their figures are shown in dollars.

Download CSV Every fund that holds BIVI, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What BioVie Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What BioVie Inc. and its lobbying firms report each quarter.

Loading…

H-1B labor applications at BioVie Inc.

0 certified in 12 mo

Labor condition applications decided by the Department of Labor, matched to BioVie Inc. by employer name. An application is not a hire.

Median yearly wage offered, full-time certified applications, Jul 2025 to Jun 2026: —

H-1B labor applications decided at BioVie Inc. by quarter
Quarter	Certified	All decided	Workers asked for
2024 Q3	0	0	0
2024 Q4	1	1	1
2025 Q1	0	0	0
2025 Q2	0	0	0
2025 Q3	0	0	0
2025 Q4	0	0	0
2026 Q1	0	0	0
2026 Q2	0	0	0

All BIVI applications

We match the employer's name to a public company automatically, including a reviewed list of subsidiaries. A subsidiary can be missed and a similar name can be matched wrongly. The files carry no worker names.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report, adjusted for splits

Funds holding the stock by quarter

Q2 2025	1	—	289	$2,674
Q3 2025	34	+33	1.20M	$2.3M
Q4 2025	37	+3	1.16M	$1.3M
Q1 2026	35	-2	1.03M	$1.4M
Q2 2026	38	+3	1.49M	$2.9M
Q3 2026	27	-11	1.71M	$2.6M

Each point is a quarter-end, from Q2 2025 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (09074F504). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q2 2025) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits (1-for-10 on Jul 7, 2025): reports from before a split are multiplied by its ratio, so every quarter is on the share count of Q3 2026.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes6 in 12 mo 8-K events3 in 90 days Patents3 patents granted Short interestFINRA · updated Oct 15 Planned insider salesNone in 12 mo Executive payNone on record Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials0 active IPO history6 registrations Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: BIOVIE INC.
Address: 680 W NYE LANE, SUITE 201, CARSON CITY, NV 89703
Phone: 775-888-3162
Fiscal year ends: Jun 30
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: NV
Listed as: BIVI (Nasdaq), BIVIW (Nasdaq)
Former names: NANOANTIBIOTICS, INC. (until 2016)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$1.13−$0.06 (−5.04%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $1.13 · High $1.73Nov 13, 2026

Aug 13, 2026Low $0.9644 · High $2.28Nov 13, 2026

Nov 13, 2025Low $0.9644 · High $2.28Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.